CCL5 and early-onset autosomal dominant Alzheimer disease: In case of Alzheimer’s disease patients treated with this type of DFPP [65], a significant reduction in the concentration of RANTES, fibrinogen, sCRP, ECP, TNF-α, and α2-macroglobulin (a marker of neuronal injury and generally increased in Alzheimer’s disease [67,68]) was evident.